Akero Therapeutics Debt To Equity vs. Current Ratio
| AKRO Stock | USD 32.17 1.01 3.24% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 0.04663501 | Current Value 0.049 | Quarterly Volatility 0.01530254 |
For Akero Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Akero Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Akero Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Akero Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Akero Therapeutics over time as well as its relative position and ranking within its peers.
Akero |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Akero Therapeutics Current Ratio vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Akero Therapeutics's current stock value. Our valuation model uses many indicators to compare Akero Therapeutics value to that of its competitors to determine the firm's financial worth. Akero Therapeutics is rated below average in debt to equity category among its peers. It is rated below average in current ratio category among its peers fabricating about 95.83 of Current Ratio per Debt To Equity. At this time, Akero Therapeutics' Debt To Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akero Therapeutics' earnings, one of the primary drivers of an investment's value.Akero Current Ratio vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Akero Therapeutics |
| = | 0.07 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Akero Therapeutics |
| = | 6.90 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Akero Current Ratio Comparison
Akero Therapeutics is currently under evaluation in current ratio category among its peers.
Akero Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Akero Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Akero Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Akero Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Akero Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 270 K | 283.5 K | |
| Operating Income | -172.9 M | -164.2 M | |
| Net Loss | -119.6 M | -125.6 M | |
| Income Before Tax | -151.8 M | -144.2 M | |
| Total Other Income Expense Net | 21.1 M | 22.2 M | |
| Net Loss | -100.8 M | -105.9 M | |
| Net Loss | -151.8 M | -144.2 M | |
| Income Tax Expense | -2.8 M | -2.7 M | |
| Interest Income | 24.2 M | 18.1 M | |
| Non Operating Income Net Other | 4.5 M | 4.7 M | |
| Net Interest Income | -2.6 M | -2.4 M | |
| Change To Netincome | 21.2 M | 25.8 M | |
| Net Loss | (2.89) | (3.03) | |
| Income Quality | 0.96 | 0.61 | |
| Net Income Per E B T | 1.12 | 1.09 |
Akero Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Akero Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Akero Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Akero Therapeutics' important profitability drivers and their relationship over time.
Use Akero Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Akero Therapeutics Pair Trading
Akero Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Akero Therapeutics position
In addition to having Akero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
To fully project Akero Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Akero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Akero Therapeutics' income statement, its balance sheet, and the statement of cash flows.